These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Clayton K. Oakley, DO, MS, MA
Advertisement
Articles by Clayton K. Oakley, DO, MS, MA
Advertisement
Latest Updated Articles
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsPublished: December 5th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
FDA Approves Revumenib in R/R NPM1-Mutant AML
5
